{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:07:43Z","timestamp":1792123663037,"version":"4.4.0"},"reference-count":79,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"14","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2025,11,21]]},"DOI":"10.1167\/iovs.66.14.53","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:30:41Z","timestamp":1763731841000},"page":"53","source":"Crossref","is-referenced-by-count":18,"title":["Can Immune Checkpoint Modulation Redefine Ocular Immunotherapy? Emerging Mechanisms, Challenges, and Translational Opportunities\u2014A Comprehensive Review"],"prefix":"10.1167","volume":"66","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of General Medicine, Chang Gung Memorial Hospital (Linkou branch), Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Cardinal Tien Hospital, New Taipei City, Taiwan"},{"name":"School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s00417-024-06422-z","article-title":"Epidemiology, clinical features, and classification of 3,404 patients with uveitis: Colombian Uveitis Multicenter Study (COL-UVEA)","volume":"262","author":"de-la-Torre","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1007\/s10792-023-02772-5","article-title":"The large Hellenic Study of Uveitis: epidemiology, etiologic factors and classification","volume":"43","author":"Kalogeropoulos","year":"2023","journal-title":"Int Ophthalmol"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/CJI.0000000000000429","article-title":"CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA methylation is associated with BAP1-aberrancy, transcriptional activity, and overall survival in uveal melanoma","volume":"45","author":"de Vos","year":"2022","journal-title":"J Immunother"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1007\/s12094-024-03495-4","article-title":"The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer","volume":"26","author":"Fei","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/path.5384","article-title":"Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development","volume":"250","author":"Figueiredo","year":"2020","journal-title":"J Pathol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/cancers14051189","article-title":"Genomic instability is defined by specific tumor microenvironment in ovarian cancer: a subgroup analysis of AGO OVAR 12 Trial","volume":"14","author":"Fumet","year":"2022","journal-title":"Cancers"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.actbio.2023.05.051","article-title":"Multifunctional nanoparticles precisely reprogram the tumor microenvironment and potentiate antitumor immunotherapy after near-infrared-II light-mediated photothermal therapy","volume":"167","author":"Ge","year":"2023","journal-title":"Acta Biomater"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"608377","DOI":"10.3389\/fimmu.2020.608377","article-title":"Immune privilege: the microbiome and uveitis","volume":"11","author":"M\u00f6lzer","year":"2020","journal-title":"Front Immunol"},{"key":"bib11","doi-asserted-by":"publisher","DOI":"10.48089\/jfo7688144","article-title":"Immune privilege in the eye","author":"Zhao","year":"2023","journal-title":"J Found Ophthalmol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3410\/B2-3","article-title":"Ocular immune privilege","volume":"2","author":"Zhou","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejphar.2016.03.001","article-title":"Targeting the complement system for the management of retinal inflammatory and degenerative diseases","volume":"787","author":"Xu","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/eye.2008.382","article-title":"Ocular immune privilege","volume":"23","author":"Taylor","year":"2009","journal-title":"Eye"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1167\/iovs.19-28632","article-title":"The eye sees eye to eye with the immune system: the 2019 Proctor Lecture","volume":"60","author":"Niederkorn","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.3390\/ijms21113962","article-title":"Immune checkpoints contribute corneal immune privilege: implications for dry eye associated with checkpoint inhibitors","volume":"21","author":"Hori","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"bib17","doi-asserted-by":"publisher","first-page":"100132","DOI":"10.1016\/j.xops.2022.100132","article-title":"Tumor-infiltrating T cells can be expanded successfully from primary uveal melanoma after separation from their tumor environment","volume":"2","author":"Gezgin","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"6","key":"bib18","doi-asserted-by":"publisher","first-page":"e006747","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J Immunother Cancer"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"1225140","DOI":"10.3389\/fimmu.2023.1225140","article-title":"The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma","volume":"14","author":"Issam Salah","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"bib20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12865-025-00697-5","article-title":"Advances in the Understanding of ocular and nasal lymphatics","volume":"26","author":"Yan","year":"2025","journal-title":"BMC Immunology"},{"issue":"8006","key":"bib21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41586-024-07130-8","article-title":"Compartmentalized ocular lymphatic system mediates eye\u2013brain immunity","volume":"628","author":"Yin","year":"2024","journal-title":"Nature"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"1679197","DOI":"10.1155\/2018\/1679197","article-title":"Immune privilege and eye-derived T-regulatory cells","volume":"2018","author":"Keino","year":"2018","journal-title":"J Immunol Res"},{"key":"bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"sup1","key":"bib24","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1080\/09273948.2016.1255761","article-title":"Epidemiology of uveitis in a tertiary-care referral institute in north India","volume":"25","author":"Dogra","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.2147\/OPTH.S273938","article-title":"Clinical features of japanese patients with ocular inflammation and their surgical procedures over the course of 20 years","volume":"14","author":"Takai","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.2217\/imt-2017-0066","article-title":"PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma","volume":"9","author":"Javed","year":"2017","journal-title":"Immunotherapy"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2174\/0929867326666190704141444","article-title":"Immunotherapy for uveal melanoma\u2014current knowledge and perspectives","volume":"27","author":"Ka\u0161telan","year":"2020","journal-title":"Curr Med Chem"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/diagnostics14030336","article-title":"Diagnosing and managing uveitis associated with immune checkpoint inhibitors: a review","volume":"14","author":"Zhang","year":"2024","journal-title":"Diagnostics"},{"issue":"1","key":"bib30","doi-asserted-by":"publisher","first-page":"e001481","DOI":"10.1136\/jitc-2020-001481","article-title":"In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis","volume":"9","author":"Kim","year":"2021","journal-title":"J Immunother Cancer"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"bib32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/IIO.0000000000000434","article-title":"Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity","volume":"62","author":"Rali","year":"2022","journal-title":"Int Ophthalmol Clin"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41433-024-03212-z","article-title":"Impact of immune checkpoint inhibitors on vision and eye health","volume":"38","author":"Masalkhi","year":"2024","journal-title":"Eye"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3389\/fonc.2019.01145","article-title":"Immunobiology of uveal melanoma: state of the art and therapeutic targets","volume":"9","author":"Basile","year":"2019","journal-title":"Front Oncol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41421-023-00521-7","article-title":"Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Cell Discov"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3390\/cancers14112638","article-title":"Pilot trial of arginine deprivation plus nivolumab and ipilimumab in patients with metastatic uveal melanoma","volume":"14","author":"Kraehenbuehl","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"bib37","doi-asserted-by":"publisher","first-page":"e70021","DOI":"10.1002\/mco2.70021","article-title":"Ocular immune-related diseases: molecular mechanisms and therapy","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"8","key":"bib38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1167\/iovs.65.8.51","article-title":"Pigment dispersion contributes to ocular immune privilege in a DBA\/2J mouse model of pigmentary glaucoma","volume":"65","author":"Li","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"bib39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.4.28","article-title":"Effects of plasma-derived exosomal miRNA-19b-3p on Treg\/T Helper 17 cell imbalance in Beh\u00e7et's uveitis","volume":"64","author":"Jiang","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exer.2015.08.012","article-title":"CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: comparison with blockade of interleukin-6","volume":"140","author":"Iwahashi","year":"2015","journal-title":"Exp Eye Res"},{"key":"bib41","first-page":"5190","article-title":"A phase I\/II dose-ranging, randomized clinical trial of abatacept (Orencia) in the treatment of refractory non-infectious uveitis: preliminary results","volume":"54","author":"Suhler","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"17588359231186027","DOI":"10.1177\/17588359231186027","article-title":"The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition","volume":"15","author":"Kreidieh","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"bib43","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1038\/s41467-024-47000-5","article-title":"Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma","volume":"15","author":"Le Saux","year":"2024","journal-title":"Nat Commun"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1080\/02713683.2022.2048396","article-title":"Two pyroptosis-related subtypes with distinct immune microenvironment characteristics and a novel signature for predicting immunotherapy response and prognosis in uveal melanoma","volume":"47","author":"Lei","year":"2022","journal-title":"Curr Eye Res"},{"key":"bib45","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3390\/biomedicines12112547","article-title":"Emerging ocular side effects of immune checkpoint inhibitors: a comprehensive review","volume":"12","author":"Wu","year":"2024","journal-title":"Biomedicines"},{"key":"bib46","article-title":"Association between immune checkpoint inhibitors and uveitis in patients with lung cancer, renal cell carcinoma, or malignant melanoma [published online ahead of print April 2, 2025]","author":"Iwai","journal-title":"Can J Ophthalmol"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"1051168","DOI":"10.3389\/fgene.2022.1051168","article-title":"GOLM1 is related to the inflammatory\/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response","volume":"13","author":"Liang","year":"2022","journal-title":"Front Genet"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/21645515.2015.1129478","article-title":"Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management","volume":"12","author":"Savoia","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/jcm14030885","article-title":"A review and comparison of immune-checkpoint inhibitors in the treatment of metastatic uveal melanoma","volume":"14","author":"Alam","year":"2025","journal-title":"J Clin Med"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"848455","DOI":"10.3389\/fimmu.2022.848455","article-title":"Landscape of infiltrated immune cell characterization in uveal melanoma to improve immune checkpoint blockade therapy","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/cancers13092043","article-title":"How to make immunotherapy an effective therapeutic choice for uveal melanoma","volume":"13","author":"Marseglia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2021.1898587","article-title":"Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment","volume":"30","author":"Masaoutis","year":"2021","journal-title":"Expert Opin Invest Drugs"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1002\/cam4.2583","article-title":"MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers","volume":"8","author":"Peng","year":"2019","journal-title":"Cancer Med"},{"issue":"6_Suppl","key":"bib54","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1158\/1538-7445.AM2024-2467","article-title":"Abstract 2467: enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumab","volume":"84","author":"Bommareddy","year":"2024","journal-title":"Cancer Res"},{"issue":"31","key":"bib55","doi-asserted-by":"publisher","first-page":"e2404375","DOI":"10.1002\/advs.202404375","article-title":"Co-delivery nano system of MS-275 and V-9302 induces pyroptosis and enhances anti-tumor immunity against uveal melanoma","volume":"11","author":"Ren","year":"2024","journal-title":"Adv Sci"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"184","DOI":"10.22336\/rjo.2020.31","article-title":"Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas","volume":"64","author":"Saftescu","year":"2020","journal-title":"Rom J Ophthalmol"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"1279387","DOI":"10.3389\/fimmu.2023.1279387","article-title":"A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses","volume":"14","author":"Smith","year":"2023","journal-title":"Front Immunol"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1159\/000524485","article-title":"Dynamic observation: immune-privileged microenvironment limited the effectiveness of immunotherapy in an intraocular metastasis mouse model","volume":"65","author":"Tao","year":"2022","journal-title":"Ophthalmic Res"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-021-01947-1","article-title":"The immune cell landscape of metastatic uveal melanoma correlates with overall survival","volume":"40","author":"Tosi","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"bib60","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1158\/2326-6066.CIR-19-0608","article-title":"CAMK1D triggers immune resistance of human tumor cells refractory to anti-PD-L1 treatment","volume":"8","author":"Volpin","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"bib61","first-page":"11201","article-title":"Tryptophan metabolism-related gene expression patterns: unveiling prognostic insights and immune landscapes in uveal melanoma","volume":"15","author":"Wang","year":"2023","journal-title":"Aging"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/15353702211053801","article-title":"Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma","volume":"247","author":"Xia","year":"2022","journal-title":"Exp Biol Med"},{"key":"bib63","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1167\/iovs.07-1606","article-title":"PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro","volume":"49","author":"Yang","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib64","doi-asserted-by":"publisher","first-page":"1758835921992989","DOI":"10.1177\/1758835921992989","article-title":"Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm","volume":"13","author":"Shahzad","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"bib65","doi-asserted-by":"publisher","first-page":"1130238","DOI":"10.3389\/fimmu.2023.1130238","article-title":"Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors","volume":"14","author":"Gan","year":"2023","journal-title":"Front Immunol"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/EB.S277760","article-title":"Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review","volume":"12","author":"Yu","year":"2020","journal-title":"Eye Brain"},{"key":"bib67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.36401\/JIPO-22-14","article-title":"Highlights on ocular toxicity of immune checkpoint inhibitors at a US tertiary cancer center","volume":"5","author":"Mazharuddin","year":"2022","journal-title":"J Immunother Precis Oncol"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/CMR.0000000000000810","article-title":"Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis","volume":"32","author":"Yu","year":"2022","journal-title":"Melanoma Res"},{"key":"bib69","doi-asserted-by":"publisher","first-page":"106633","DOI":"10.1016\/j.intimp.2020.106633","article-title":"Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer types","volume":"85","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"bib70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.trecan.2017.11.005","article-title":"Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive \u2018cold\u2019 tumors \u2018hot\u2019","volume":"4","author":"Prendergast","year":"2018","journal-title":"Trends Cancer"},{"key":"bib71","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3389\/fimmu.2018.01567","article-title":"Soluble CD83 alleviates experimental autoimmune uveitis by inhibiting filamentous actin-dependent calcium release in dendritic cells","volume":"9","author":"Lin","year":"2018","journal-title":"Front Immunol"},{"key":"bib72","doi-asserted-by":"publisher","first-page":"721030","DOI":"10.3389\/fimmu.2021.721030","article-title":"Pan-cancer analysis of PARP1 alterations as biomarkers in the prediction of immunotherapeutic effects and the association of its expression levels and immunotherapy signatures","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"bib73","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/cancers13102288","article-title":"CD137 as an attractive T cell co-stimulatory target in the TNFRSF for immuno-oncology drug development","volume":"13","author":"Hashimoto","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"Suppl 3","key":"bib74","first-page":"e000733","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","volume":"4","author":"Etxeberria","year":"2020","journal-title":"ESMO Open"},{"key":"bib75","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1167\/iovs.04-0835","article-title":"Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells","volume":"46","author":"Shao","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib76","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4110\/in.2010.10.3.104","article-title":"Agonistic anti-CD137 monoclonal antibody treatment induces CD11bGr-1 myeloid-derived suppressor cells","volume":"10","author":"Lee","year":"2010","journal-title":"Immune Netw"},{"issue":"1","key":"bib77","doi-asserted-by":"publisher","first-page":"6360","DOI":"10.1038\/s41467-021-26645-6","article-title":"Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity","volume":"12","author":"Qiao","year":"2021","journal-title":"Nat Commun"},{"key":"bib78","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/2211-5463.13494","article-title":"Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates","volume":"12","author":"Gao","year":"2022","journal-title":"FEBS Open Bio"},{"key":"bib79","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bjo-2022-322913","article-title":"Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1\/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients","volume":"108","author":"Kashyap","year":"2024","journal-title":"Br J Ophthalmol"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2811140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:32:07Z","timestamp":1791927127000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2811140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":79,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.66.14.53","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}